Navneet Singh

Navneet Singh

Auto-generated profile, based on publicly available information

Navneet Singh

Brown University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
NSNavneet Singh
Navneet Singh
PDPeter Dorfmüller
Peter Dorfmüller
OSOksana A. Shlobin
Oksana A. Shlobin
CVCorey Ventetuolo
Corey Ventetuolo
Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.

24 November 2025 in Comprehensive Physiology
Verified
Journal Article
Open access
AJArun Jose
Arun Jose
HDHilary M. DuBrock
Hilary M. DuBrock
NSNavneet Singh
Navneet Singh
JKJay Kolls
Jay Kolls
MKMichael Krowka
Michael Krowka
URUsha Raj
Usha Raj

1 October 2025 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
NSNavneet Singh
Navneet Singh
CKCeren Kocana
Ceren Kocana
ESEric P. Schmidt
Eric P. Schmidt
MHMark L. Hepokoski
Mark L. Hepokoski
MMMichael A. Matthay
Michael A. Matthay
TSTroy Stevens
Troy Stevens
Session V of the inaugural biennial Research Symposium on Pulmonary Injury and Repair of the Endothelium showcased cutting-edge research on pulmonary endothelial crosstalk with end organs and its role in vascular disease. Growing evidence suggests that communication between injured organs and distal vascular beds plays a critical role in the pathogenesis of complex conditions such as sepsis, acute respiratory distress syndrome, pulmonary arterial hypertension, and heart failure with preserved ejection fraction. Circulating mediators—including heparan sulfate fragments, proinflammatory cytokines, mitochondrial damage-associated molecular patterns, bone morphogenetic protein 9, bile acids, and nitric oxide—have emerged as key factors linking pulmonary endothelial dysfunction to neural impairment, acute kidney injury, subclinical liver injury, and left-sided heart disease. This review highlights recent advances in the field, identifies critical knowledge gaps, and outlines future research directions aimed at elucidating mechanisms of multiorgan dysfunction and identifying novel therapeutic targets.

3 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
RSRachel Sanders
Rachel Sanders
TWThomas Walsh
Thomas Walsh
GBGrayson L. Baird
Grayson L. Baird
MAMichael K. Atalay
Michael K. Atalay
SASaurabh Agarwal
Saurabh Agarwal
CVCorey Ventetuolo
Corey Ventetuolo
Rationale: The adrenal steroid dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S) are deficient in pulmonary arterial hypertension (PAH) and lower levels are associated with worse right ventricular (RV) function, a decisive factor for survival in PAH. Objectives: We sought to determine whether DHEA improved RV function as measured by cardiac magnetic resonance imaging (MRI) in PAH. Methods: We conducted a randomized, double-blind, placebo-controlled crossover clinical trial of DHEA in participants with PAH at a single center. All participants and study staff were blinded. The primary outcome was change in RV longitudinal strain as measured by MRI after 18 weeks. Key secondary outcomes were the change in serum DHEA-S levels and other PAH end points after 18 weeks. Measurements and Main Results: A total of 26 participants were randomized to DHEA first or placebo first between 2019 and 2024, 20 (77%) of whom were females. Twenty- three (88%) participants completed the study; one participant completely withdrew. DHEA had no effect on RV longitudinal strain. DHEA improved RV short axis radial strain (20.7% [95% CI 16.7, 24.6] to 23.1% [95% CI 19.5, 26.7] compared to placebo (21.1% [95% CI 18.1, 24.0] to 19.3% [95% CI 16.5, 22.2])(p = 0.031), as well as emPHasis-10 scores (p = 0.037) and Short Form-36 physical component scores (p = 0.044) in the second treatment period. In both treatment periods, DHEA may have worsened RV circumferential strain as compared to placebo (p = 0.047, p = 0.052 respectively). Active treatment with DHEA significantly increased serum DHEA-S levels at the end of both treatment periods (p<0.0001), which was in turn associated with multiple study end points in the predicted direction (higher DHEA-S levels, improved PAH metrics). Active treatment with DHEA significantly increased serum testosterone levels as compared to placebo (p <0.01 for both treatment periods), which may have counteracted effects of DHEA supplementation. There was no difference in adverse events. Conclusions: DHEA treatment did not improve RV longitudinal strain in this pilot crossover trial but had variable and possibly beneficial effects on other PAH endpoints. DHEA increased DHEA-S and testosterone levels, which may explain some of the discordant results. DHEA is safe and well tolerated in PAH. Clinical trial registered with www.clinicaltrials.gov ( NCT03648385 )

1 January 2025 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
SPSunita S. Paudel
Sunita S. Paudel
NSNavneet Singh
Navneet Singh
DTDhananjay T. Tambe
Dhananjay T. Tambe
GBGlen M. Borchert
Glen M. Borchert
SCScott A. Collins
Scott A. Collins
CVCorey Ventetuolo
Corey Ventetuolo

1 May 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
NSNavneet Singh
Navneet Singh
CVCorey Ventetuolo
Corey Ventetuolo